A Phase 2/3 interventional study of Atogepant and Placebo-matching Atogepant in Migraine, With or Without Aura, sponsored by Allergan. Completed at 75 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-12-06.
Sponsored by Allergan (part of AbbVie) · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.
Among the 21 studies testing atogepant in Migraine Disorders, this one is the 4th largest by enrollment, is the only one that started in 2016, is the only one in phase 2/3, and was the 1st registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Canada, Denmark and 8 more countries
Ages 12–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
Konrad Peter Weber · Sites in Switzerland
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 16 · Phase 4 4
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 834 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 468 across the 21 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 5 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 9th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2016, is the only one in phase 2/3, and was the 18th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing atogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo-matching atogepant capsule orally twice daily in the morning and in the evening for 12 weeks.
Drug: Placebo-matching Atogepant
Atogepant 10 mg capsule orally once daily (QD) in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
Drug: Atogepant · Drug: Placebo-matching Atogepant
Atogepant 30 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
Drug: Atogepant · Drug: Placebo-matching Atogepant
Atogepant 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
Drug: Atogepant
Atogepant 60 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally in the evening for 12 weeks.
Drug: Atogepant · Drug: Placebo-matching Atogepant
Atogepant 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
Drug: Atogepant
Atogepant capsule.
Also known as: AGN-241689
Placebo-matching atogepant capsule.
Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period
Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration and acute symptomatic medication use. The 4-week migraine days was defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4- week period and multiplied by 28. Each 4-week period was averaged. Negative change from Baseline indicates improvement.
Time frame: Baseline (First 28 Days of Screening/Baseline Period) to Week 12
Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period
Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache qualified by duration and acute symptomatic medication use. The 4-week (monthly) headache days was defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Negative change from Baseline indicates improvement.
Time frame: Baseline (First 28 Days of Screening/Baseline Period) to Week 12
Percentage of Participants With at Least a 50% Reduction in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period
Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration and acute symptomatic medication use. The 4-week migraine days=total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. Each 4-week period was averaged.
Time frame: Baseline (First 28 Days of Screening/Baseline Period) to Week 12
Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period
Participants recorded allowed medication(s) to treat an acute migraine in the daily diary. The 4-week (monthly) acute medication use days was defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. A negative change from Baseline indicates improvement.
Time frame: Baseline (First 28 Days of Screening/Baseline Period) to Week 12
| Milestone | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID |
|---|---|---|---|---|---|---|
| Started | 186 | 94 | 185 | 187 | 89 | 93 |
| Safety population: received study drug | 186 | 93 | 183 | 186 | 86 | 91 |
| Completed | 148 | 80 | 149 | 164 | 70 | 73 |
| Not completed | 38 | 14 | 36 | 23 | 19 | 20 |
| Withdrew: Adverse event | 5 | 4 | 11 | 6 | 5 | 7 |
| Withdrew: Withdrawal of consent | 20 | 6 | 9 | 6 | 9 | 6 |
| Withdrew: Lost to follow-up | 5 | 1 | 11 | 7 | 2 | 3 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 4 | 3 | 4 | 2 | 3 | 3 |
| Withdrew: Non-compliance with study drug | 4 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID |
|---|---|---|---|---|---|---|
| Started | 161 | 84 | 156 | 169 | 77 | 82 |
| Completed | 157 | 83 | 153 | 169 | 76 | 77 |
| Not completed | 4 | 1 | 3 | 0 | 1 | 5 |
| Withdrew: Withdrawal of consent | 0 | 1 | 1 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 4 | 0 | 2 | 0 | 1 | 3 |
Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration and acute symptomatic medication use. The 4-week migraine days was defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4- week period and multiplied by 28. Each 4-week period was averaged. Negative change from Baseline indicates improvement.
| migraine days per month | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period | -2.85 ± 0.23 | -4.00 ± 0.32 | -3.76 ± 0.23 | -3.55 ± 0.23 | -4.23 ± 0.35 | -4.14 ± 0.33 |
Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache qualified by duration and acute symptomatic medication use. The 4-week (monthly) headache days was defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Negative change from Baseline indicates improvement.
| headache days per month | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period | -2.93 ± 0.25 | -4.31 ± 0.35 | -4.17 ± 0.25 | -3.86 ± 0.25 | -4.23 ± 0.38 | -4.32 ± 0.36 |
Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration and acute symptomatic medication use. The 4-week migraine days=total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. Each 4-week period was averaged.
| percentage of participants | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants With at Least a 50% Reduction in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period | 40.4 | 57.6 | 53.3 | 52.0 | 58.2 | 62.1 |
Participants recorded allowed medication(s) to treat an acute migraine in the daily diary. The 4-week (monthly) acute medication use days was defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. A negative change from Baseline indicates improvement.
| acute medication use days per month | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period | -2.42 ± 0.21 | -3.71 ± 0.29 | -3.86 ± 0.20 | -3.53 ± 0.21 | -3.77 ± 0.31 | -3.64 ± 0.29 |
Collected over Up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/186 (0%) | 2/186 (1.1%) | 36/186 (19.4%) |
| Atogepant 10 mg QD | 0/93 (0%) | 1/93 (1.1%) | 17/93 (18.3%) |
| Atogepant 30 mg QD | 0/183 (0%) | 2/183 (1.1%) | 47/183 (25.7%) |
| Atogepant 60 mg QD | 0/186 (0%) | 2/186 (1.1%) | 52/186 (28%) |
| Atogepant 30 mg BID | 0/86 (0%) | 0/86 (0%) | 21/86 (24.4%) |
| Atogepant 60 mg BID | 0/91 (0%) | 0/91 (0%) | 26/91 (28.6%) |
| Event | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID |
|---|---|---|---|---|---|---|
| CholecystitisHepatobiliary disorders | 0/186 | 1/93 | 0/183 | 0/186 | 0/86 | 0/91 |
| UreteritisInfections and infestations | 0/186 | 0/93 | 1/183 | 0/186 | 0/86 | 0/91 |
| MigraineNervous system disorders | 0/186 | 0/93 | 1/183 | 0/186 | 0/86 | 0/91 |
| AbortionPregnancy, puerperium and perinatal conditions | 0/186 | 0/93 | 0/183 | 1/186 | 0/86 | 0/91 |
| Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/186 | 0/93 | 0/183 | 0/186 | 0/86 | 0/91 |
| OverdosePsychiatric disorders | 0/186 | 0/93 | 0/183 | 1/186 | 0/86 | 0/91 |
| Major depressionPsychiatric disorders | 0/186 | 0/93 | 0/183 | 1/186 | 0/86 | 0/91 |
| UreterolithiasisRenal and urinary disorders | 1/186 | 0/93 | 0/183 | 0/186 | 0/86 | 0/91 |
| Event | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 9/186 | 5/93 | 13/183 | 21/186 | 7/86 | 9/91 |
| FatigueGeneral disorders | 6/186 | 1/93 | 3/183 | 5/186 | 2/86 | 9/91 |
| Upper respiratory tract infectionInfections and infestations | 14/186 | 6/93 | 13/183 | 9/186 | 4/86 | 6/91 |
| NasopharyngitisInfections and infestations | 4/186 | 3/93 | 10/183 | 14/186 | 1/86 | 1/91 |
| ConstipationGastrointestinal disorders | 4/186 | 2/93 | 10/183 | 9/186 | 3/86 | 6/91 |
| Blood creatine phosphokinase increasedInvestigations | 2/186 | 3/93 | 3/183 | 2/186 | 5/86 | 2/91 |
Safety Population included all participants who received at least 1 dose of study treatment.
| Age, Continuous(years) | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Mean | 40.5 ± 11.7 | 39.4 ± 12.4 | 41.0 ± 13.6 | 40.4 ± 11.7 | 38.5 ± 11.2 | 39.7 ± 11.9 | 40.1 ± 12.2 |
| Sex: Female, Male(Participants) | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Female | 154 | 82 | 166 | 156 | 73 | 83 | 714 |
| Male | 32 | 11 | 17 | 30 | 13 | 8 | 111 |
| Race/Ethnicity, Customized(Participants) | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID | Total |
|---|---|---|---|---|---|---|---|
| White | 137 | 69 | 145 | 133 | 73 | 71 | 628 |
| Black or African American | 45 | 20 | 29 | 44 | 11 | 19 | 168 |
| Asian | 1 | 1 | 2 | 3 | 1 | 0 | 8 |
| American Indian or Alaska Native | 3 | 0 | 1 | 2 | 0 | 0 | 6 |
| Native Hawaiian/Other Pacific Islander | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Multiple Races | 0 | 3 | 4 | 4 | 1 | 1 | 13 |
| Race/Ethnicity, Customized(Participants) | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 29 | 15 | 32 | 25 | 13 | 13 | 127 |
| Not Hispanic or Latino | 157 | 78 | 151 | 161 | 73 | 78 | 698 |
| Migraine Days (Migraine/Probable Migraine Headache Days)(migraine days per month) | Placebo | Atogepant 10 mg QD | Atogepant 30 mg QD | Atogepant 60 mg QD | Atogepant 30 mg BID | Atogepant 60 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Mean | 7.81 ± 2.51 | 7.63 ± 2.51 | 7.64 ± 2.37 | 7.74 ± 2.59 | 7.38 ± 2.43 | 7.62 ± 2.56 | 7.67 ± 2.49 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Apr 2018, 18 months.
Results were first posted in Dec 2018, 8 months after primary completion.
Of 12 phase 2/3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 18 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atogepant